GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Follow-Up Questions
Who is the CEO of GSK plc?
Dame Emma Walmsley is the Chief Executive Officer of GSK plc, joining the firm since 2011.
What is the price performance of GSK stock?
The current price of GSK is $46.82, it has decreased 0% in the last trading day.
What are the primary business themes or industries for GSK plc?
GSK plc belongs to Pharmaceuticals industry and the sector is Health Care
What is GSK plc market cap?
GSK plc's current market cap is $94.1B
Is GSK plc a buy, sell, or hold?
According to wall street analysts, 23 analysts have made analyst ratings for GSK plc, including 5 strong buy, 7 buy, 15 hold, 4 sell, and 5 strong sell
